| Year |
Citation |
Score |
| 2020 |
Chen Y, Das S, Pandya D, Billaud J, Reva A, Roth A, Dottino PR, Hakonarson H, Martignetti J. Development and validation of targeted treatments for the rare tumor syndrome infantile myofibromatosis. Journal of Clinical Oncology. 38. DOI: 10.1200/Jco.2020.38.15_Suppl.E22519 |
0.344 |
|
| 2019 |
Song X, Ji J, Gleason KJ, Yang F, Martignetti JA, Chen LS, Wang P. Insights into impact of DNA copy number alteration and methylation on the proteogenomic landscape in human ovarian cancer via a multi-omics integrative analysis. Molecular & Cellular Proteomics : McP. PMID 31227599 DOI: 10.1074/Mcp.Ra118.001220 |
0.374 |
|
| 2019 |
Pandya DS, Tomita S, Camacho O, Swierczek S, Camacho C, Engelman K, Polukort S, Padron MM, RoseFigura J, Irish J, Chuang L, Andikyan V, Cohen S, Fiedler P, Sieber S, ... ... Martignetti JA, et al. Abstract 2729: Development of a targeted liquid biopsy for early gynecologic cancer detection leads to discovery of a highly prevalent genomic landscape of cancer driver gene mutations in uterine tissue from women without cancer Cancer Research. 79: 2729-2729. DOI: 10.1158/1538-7445.Am2019-2729 |
0.426 |
|
| 2019 |
Pandya D, Camacho-Vanegas O, Camacho SC, Dottino P, Martignetti JA. Targeted Liquid Biopsy Detects Tumor-Specific TP53 Mutations in Early and Late Stage Ovarian Cancer [29O] Obstetrics & Gynecology. 133: 170-170. DOI: 10.1097/01.Aog.0000559484.56419.39 |
0.381 |
|
| 2019 |
Padron MMM, Camacho-Vanegas O, Pandya D, Camacho SC, Dottino P, Martignetti JA. Use of a Targeted Lynch Syndrome Next Generation Sequencing Panel in Women at Risk for or With Endometrial Cancer [32M] Obstetrics & Gynecology. 133: 149S-150S. DOI: 10.1097/01.Aog.0000559305.68974.C9 |
0.36 |
|
| 2018 |
Martignetti JA, Pandya D, Nagarsheth N, Chen Y, Camacho O, Tomita S, Brodman M, Ascher-Walsh C, Kolev V, Cohen S, Harkins T, Schadt E, Reva B, Sebra R, Dottino P. Detection of endometrial precancer by a targeted gynecologic cancer liquid biopsy. Cold Spring Harbor Molecular Case Studies. PMID 30301868 DOI: 10.1101/mcs.a003269 |
0.309 |
|
| 2018 |
Schwartz M, Camacho-Vanegas O, Wood AM, Dashkoff M, Whitelock C, Harkins TT, Cohen CJ, Beddoe AM, Dottino P, Martignetti JA. Applying Precision Medicine to Ovarian Cancer: Proof-of-Principle for a "Molecular Second Look". International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. PMID 29324546 DOI: 10.1097/Igc.0000000000001190 |
0.396 |
|
| 2018 |
Beaumont K, Copperman AB, Dottino P, Martignetti J, Schadt E, Sebra R. Multiparameter Single Cell Characterization of Ovarian Intratumor Heterogeneity [29A] Obstetrics & Gynecology. 131. DOI: 10.1097/01.Aog.0000532892.87767.De |
0.324 |
|
| 2017 |
Wood A, Sandhu S, Dashkoff M, Camacho-Vanegas O, Kurihara L, Harkins T, Martignetti J, Makarov V, Dottino P. Abstract LB-276: Characterizing tumorigenesis of ovarian cancer across metastatic tumors and circulating, cell-free DNA Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Lb-276 |
0.384 |
|
| 2017 |
Irish JC, Schumacher CA, Nair N, Camacho-Vanegas O, Figura JR, Wood A, Sandhu S, Chaluvadi S, Chupreta S, Kurihara L, Harkins T, Martignetti JA, Makarov V. Abstract 5392: Targeted next-generation sequencing of cell-free tumor DNA to longitudinally monitor cancer burden and progression Cancer Research. 77: 5392-5392. DOI: 10.1158/1538-7445.Am2017-5392 |
0.402 |
|
| 2017 |
Martignetti J, Nair N, Vanegas O, Rykunov D, Dashkoff M, Camacho S, Harkins T, Schumacher C, Irish J, Pereira E, Kendall S, Kalir T, Sebra R, Reva B, Dottino P. Mutation profiling of uterine lavage fluid detects early-stage endometrial cancers and discovers a prevalent landscape of driver mutations in women without cancer Gynecologic Oncology. 145: 126. DOI: 10.1016/J.Ygyno.2017.03.294 |
0.375 |
|
| 2016 |
Nair N, Camacho-Vanegas O, Rykunov D, Dashkoff M, Camacho SC, Schumacher CA, Irish JC, Harkins TT, Freeman E, Garcia I, Pereira E, Kendall S, Belfer R, Kalir T, Sebra R, ... ... Martignetti JA, et al. Genomic Analysis of Uterine Lavage Fluid Detects Early Endometrial Cancers and Reveals a Prevalent Landscape of Driver Mutations in Women without Histopathologic Evidence of Cancer: A Prospective Cross-Sectional Study. Plos Medicine. 13: e1002206. PMID 28027320 DOI: 10.1371/Journal.Pmed.1002206 |
0.379 |
|
| 2016 |
Martignetti JA, Chen Y, Camacho C, Silvers TR, Razak AR, Gabrail NY, Gerecitano JF, Kalir E, Pereira E, Evans BR, Ramus SJ, Huang F, Priedigkeit N, Rodriguez E, Donovan M, et al. INHIBITION OF THE NUCLEAR EXPORT RECEPTOR XPO1 AS A THERAPEUTIC TARGET FOR PLATINUM RESISTANT OVARIAN CANCER. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27649553 DOI: 10.1158/1078-0432.Ccr-16-1333 |
0.363 |
|
| 2016 |
Silvers TR, Dottino PR, Martignetti JA, Evans BR. Abstract B75: Increased basal autophagy decreases sensitivity to cisplatin in chemoresistant ovarian cancer. Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Ovca15-B75 |
0.323 |
|
| 2016 |
Pereira E, Vanegas O, Anand S, Sebra R, Vanegas S, Garnar-Wortzel L, Nair N, Moshier E, Wooten M, Uzilov A, Chen R, Hayes M, Zakashansky K, Beddoe A, Schadt E, ... ... Martignetti J, et al. Personalized circulating tumor DNA biomarkers dynamically predict treatment response and survival in gynecologic cancers Gynecologic Oncology. 141: 3-4. DOI: 10.1016/J.Ygyno.2016.04.036 |
0.34 |
|
| 2015 |
Pereira E, Camacho-Vanegas O, Anand S, Sebra R, Catalina Camacho S, Garnar-Wortzel L, Nair N, Moshier E, Wooten M, Uzilov A, Chen R, Prasad-Hayes M, Zakashansky K, Beddoe AM, Schadt E, ... ... Martignetti JA, et al. Personalized Circulating Tumor DNA Biomarkers Dynamically Predict Treatment Response and Survival In Gynecologic Cancers. Plos One. 10: e0145754. PMID 26717006 DOI: 10.1371/Journal.Pone.0145754 |
0.375 |
|
| 2015 |
Rubinsteyn A, Martignetti J, Pereira E, O'Donnell T, Ahuja A, Garnar-Wortzel L, Sebra R, Dottino P, Hammerbacher J, Schadt E. Heterogeneity of mutated tumor antigens in a single high grade ovarian serous carcinoma F1000research. 6. DOI: 10.7490/F1000Research.1098264.1 |
0.378 |
|
| 2015 |
Pereira EB, Camacho-Vanegas O, Anand S, Singh C, Uzilov A, Sebra R, Chappell D, Dottino P, Martignetti JA. Abstract 2398: Precision molecular biomarkers for the surveillance of gynecologic malignancies: Rapid and efficient pipeline for the design and highly sensitive detection of circulating tumor DNA Cancer Research. 75: 2398-2398. DOI: 10.1158/1538-7445.Am2015-2398 |
0.414 |
|
| 2015 |
Evans BR, Silvers TR, Chen YA, Garcia J, Camacho C, Sharp AJ, Garag P, Koduru SV, Billaud J, Halpert RL, Dottino PR, Landesman Y, Shacham S, Martignetti JA. Abstract 1758: Deconstructing protein and gene expression pathways to define the anticancer effects of XPO1 inhibition in ovarian cancer Cancer Research. 75: 1758-1758. DOI: 10.1158/1538-7445.Am2015-1758 |
0.397 |
|
| 2014 |
Martignetti J, Razak AR, Chen Y, Gabrail NY, Gericitano JF, Camacho C, Pereira E, Evans B, Dottino P, McCauley D, Shacham S, Rashal T, Saint-Martin J, Shacham E, Vincent D, et al. 888PPRECLINICAL AND EARLY CLINICAL ACTIVITY OF THE ORAL SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) EXPORTIN 1 (XPO1) ANTAGONIST SELINEXOR (KPT-330) IN PATIENTS (PTS) WITH PLATINUM RESISTANT/REFRACTORY OVARIAN CANCER (OVCA). Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv310. PMID 28170968 DOI: 10.1093/Annonc/Mdu338.14 |
0.314 |
|
| 2014 |
Cohen S, Mosig R, Moshier E, Pereira E, Rahaman J, Prasad-Hayes M, Halpert R, Billaud JN, Dottino P, Martignetti JA. Interferon regulatory factor 1 is an independent predictor of platinum resistance and survival in high-grade serous ovarian carcinoma. Gynecologic Oncology. 134: 591-8. PMID 24995581 DOI: 10.1016/J.Ygyno.2014.06.025 |
0.765 |
|
| 2014 |
Wang Z, Wu B, Mosig RA, Chen Y, Ye F, Zhang Y, Gong W, Gong L, Huang F, Wang X, Nie B, Zheng H, Cui M, Wang Y, Wang J, ... ... Martignetti JA, et al. STK11 domain XI mutations: candidate genetic drivers leading to the development of dysplastic polyps in Peutz-Jeghers syndrome. Human Mutation. 35: 851-8. PMID 24652667 DOI: 10.1002/Humu.22549 |
0.764 |
|
| 2014 |
Martignetti JA, Camacho-Vanegas O, Priedigkeit N, Camacho C, Pereira E, Lin L, Garnar-Wortzel L, Miller D, Losic B, Shah H, Liao J, Ma J, Lahiri P, Chee M, Schadt E, et al. Personalized ovarian cancer disease surveillance and detection of candidate therapeutic drug target in circulating tumor DNA. Neoplasia (New York, N.Y.). 16: 97-103. PMID 24563622 DOI: 10.1593/Neo.131900 |
0.391 |
|
| 2014 |
Martignetti J, Razak ARA, Chen Y, Gabrail NY, Gerecitano JF, Camacho C, Pereira E, Dottino PR, Shacham S, McCauley D, Rashal T, Saint-Martin J, Shacham E, Vincett D, Kauffman M, et al. Preclinical and early clinical activity of the oral selective inhibitor of nuclear export (SINE) exportin 1 (XPO1) antagonist KPT-330 (Selinexor) in patients (pts) with platinum-resistant/refractory ovarian cancer (OvCa). Journal of Clinical Oncology. 32: 5522-5522. DOI: 10.1200/Jco.2014.32.15_Suppl.5522 |
0.379 |
|
| 2014 |
Martignetti JA, Cohen S, Mosig R, Halpert R, Billaud J, Dottino P. Abstract 5593: Transcriptome and pathway analysis identifies IRF1 as a predictor of progression free and overall survival in ovarian carcinoma Cancer Research. 74: 5593-5593. DOI: 10.1158/1538-7445.Am2014-5593 |
0.774 |
|
| 2014 |
Martignetti JA, Camacho-Vanegas O, Priedigkeit N, Camacho-Vanegas C, Pereira E, Lin L, Losic B, Shah h, Liao J, Ma J, Lahiri P, Chee M, Schadt E, Dottino P. Abstract 4712: Personalized ovarian cancer surveillance and detection of a therapeutic drug target in circulating tumor DNA Cancer Research. 74: 4712-4712. DOI: 10.1158/1538-7445.Am2014-4712 |
0.394 |
|
| 2014 |
Billaud J, Cohen S, Mosig R, Halpert R, Dottino P, Martignetti J. 869: Transcriptome and pathway analysis identifies IRF1 as a predictor of progression free and overall survival in ovarian carcinoma European Journal of Cancer. 50. DOI: 10.1016/S0959-8049(14)50772-1 |
0.743 |
|
| 2014 |
Pereira EB, Evans B, Vanegas OC, Dottino P, Martignetti J. Establishment and combined genomic and proteomic characterization of patient-derived ovarian cancer cell lines Gynecologic Oncology. 133: 125. DOI: 10.1016/J.Ygyno.2014.03.327 |
0.333 |
|
| 2013 |
Castberg FC, Kjaergaard S, Mosig RA, Lobl M, Martignetti C, Martignetti JA, Myrup C, Zak M. Multicentric osteolysis with nodulosis and arthropathy (MONA) with cardiac malformation, mimicking polyarticular juvenile idiopathic arthritis: case report and literature review. European Journal of Pediatrics. 172: 1657-63. PMID 23900523 DOI: 10.1007/S00431-013-2102-8 |
0.737 |
|
| 2013 |
Martignetti JA, Tian L, Li D, Ramirez MC, Camacho-Vanegas O, Camacho SC, Guo Y, Zand DJ, Bernstein AM, Masur SK, Kim CE, Otieno FG, Hou C, Abdel-Magid N, Tweddale B, et al. Mutations in PDGFRB cause autosomal-dominant infantile myofibromatosis. American Journal of Human Genetics. 92: 1001-7. PMID 23731542 DOI: 10.1016/J.Ajhg.2013.04.024 |
0.363 |
|
| 2013 |
Camacho-Vanegas O, Till J, Miranda-Lorenzo I, Ozturk B, Camacho SC, Martignetti JA. Shaking the family tree: identification of novel and biologically active alternatively spliced isoforms across the KLF family of transcription factors. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 27: 432-6. PMID 23134681 DOI: 10.1096/Fj.12-220319 |
0.347 |
|
| 2013 |
Mosig RA, Martignetti JA. Loss of MMP-2 in murine osteoblasts upregulates osteopontin and bone sialoprotein expression in a circuit regulating bone homeostasis. Disease Models & Mechanisms. 6: 397-403. PMID 22917927 DOI: 10.1242/Dmm.007914 |
0.755 |
|
| 2013 |
Favier R, DiFeo A, Hezard N, Fabre M, Bedossa P, Martignetti JA. A new feature of the MYH9-related syndrome: chronic transaminase elevation. Hepatology (Baltimore, Md.). 57: 1288-9. PMID 22806255 DOI: 10.1002/Hep.25913 |
0.52 |
|
| 2013 |
Chen Y, Kalir E, Camacho-Vanegas C, Huang F, Pereira E, Landesman Y, McCauley D, Mirza MR, Kauffman M, Shacham S, Dottino PR, Martignetti JA. Abstract 2163: Increased overall survival in platinum-resistant ovarian cancer: paradigmatic use of novel SINE (selective inhibitor of nuclear export), which restores p53 nuclear localization and activation. Cancer Research. 73: 2163-2163. DOI: 10.1158/1538-7445.Am2013-2163 |
0.391 |
|
| 2012 |
Evans BR, Mosig RA, Lobl M, Martignetti CR, Camacho C, Grum-Tokars V, Glucksman MJ, Martignetti JA. Mutation of membrane type-1 metalloproteinase, MT1-MMP, causes the multicentric osteolysis and arthritis disease Winchester syndrome. American Journal of Human Genetics. 91: 572-6. PMID 22922033 DOI: 10.1016/J.Ajhg.2012.07.022 |
0.752 |
|
| 2012 |
Camacho-Vanegas O, Camacho SC, Till J, Miranda-Lorenzo I, Terzo E, Ramirez MC, Schramm V, Cordovano G, Watts G, Mehta S, Kimonis V, Hoch B, Philibert KD, Raabe CA, Bishop DF, ... ... Martignetti JA, et al. Primate genome gain and loss: a bone dysplasia, muscular dystrophy, and bone cancer syndrome resulting from mutated retroviral-derived MTAP transcripts. American Journal of Human Genetics. 90: 614-27. PMID 22464254 DOI: 10.1016/J.Ajhg.2012.02.024 |
0.42 |
|
| 2012 |
Calderon MR, Verway M, An BS, DiFeo A, Bismar TA, Ann DK, Martignetti JA, Shalom-Barak T, White JH. Ligand-dependent corepressor (LCoR) recruitment by Kruppel-like factor 6 (KLF6) regulates expression of the cyclin-dependent kinase inhibitor CDKN1A gene. The Journal of Biological Chemistry. 287: 8662-74. PMID 22277651 DOI: 10.1074/Jbc.M111.311605 |
0.634 |
|
| 2012 |
Mosig RA, Lin L, Senturk E, Shah H, Huang F, Schlosshauer P, Cohen S, Fruscio R, Marchini S, D'Incalci M, Sachidanandam R, Dottino P, Martignetti JA. Application of RNA-Seq transcriptome analysis: CD151 is an Invasion/Migration target in all stages of epithelial ovarian cancer. Journal of Ovarian Research. 5: 4. PMID 22272937 DOI: 10.1186/1757-2215-5-4 |
0.775 |
|
| 2012 |
Mosig RA, Lobl M, Senturk E, Shah H, Cohen S, Chudin E, Fruscio R, Marchini S, D'Incalci M, Sachidanandam R, Dottino P, Martignetti JA. IGFBP-4 tumor and serum levels are increased across all stages of epithelial ovarian cancer. Journal of Ovarian Research. 5: 3. PMID 22264331 DOI: 10.1186/1757-2215-5-3 |
0.774 |
|
| 2012 |
Camacho-Vanegas O, Camacho SC, Till J, Miranda-Lorenzo I, Terzo E, Ramirez MC, Schramm V, Cordovano G, Watts G, Mehta S, Kimonis V, Hoch B, Philibert KD, Raabe CA, Bishop DF, ... ... Martignetti JA, et al. Abstract LB-89: Discovery and characterization of novel MTAP splice variants resulting in a hereditary form of osteosarcoma and demonstration of their dysregulation in sporadic forms of this cancer Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Lb-89 |
0.464 |
|
| 2012 |
Chen Y, Kalir E, Priedigkeit N, Kalir T, Liu Y, Hu W, Sood A, Radu A, Dottino P, Martignetti J. Follicle-stimulating hormone receptor expression analysis in serous ovarian tumors suggests a disease continuum from low malignant potential to low-grade carcinoma Gynecologic Oncology. 125. DOI: 10.1016/J.Ygyno.2011.12.348 |
0.331 |
|
| 2012 |
Mosig R, Lobl M, Cohen S, Chudin E, Fruscio R, Marchini S, D'Incalci M, Sachidanandam R, Dottino P, Martignetti J. Insulin-like growth factor binding protein-4 (IGFBP-4) tumor and serum levels are increased across all stages of epithelial ovarian cancer Gynecologic Oncology. 125. DOI: 10.1016/J.Ygyno.2011.12.225 |
0.759 |
|
| 2011 |
Sanborn KB, Mace EM, Rak GD, Difeo A, Martignetti JA, Pecci A, Bussel JB, Favier R, Orange JS. Phosphorylation of the myosin IIA tailpiece regulates single myosin IIA molecule association with lytic granules to promote NK-cell cytotoxicity. Blood. 118: 5862-71. PMID 22123909 DOI: 10.1182/Blood-2011-03-344846 |
0.575 |
|
| 2011 |
Agnani D, Camacho-Vanegas O, Camacho C, Lele S, Odunsi K, Cohen S, Dottino P, Martignetti JA. Decreased levels of serum glutathione peroxidase 3 are associated with papillary serous ovarian cancer and disease progression. Journal of Ovarian Research. 4: 18. PMID 22017790 DOI: 10.1186/1757-2215-4-18 |
0.388 |
|
| 2011 |
Deuquet J, Lausch E, Guex N, Abrami L, Salvi S, Lakkaraju A, Ramirez MC, Martignetti JA, Rokicki D, Bonafe L, Superti-Furga A, van der Goot FG. Hyaline fibromatosis syndrome inducing mutations in the ectodomain of anthrax toxin receptor 2 can be rescued by proteasome inhibitors. Embo Molecular Medicine. 3: 208-21. PMID 21328543 DOI: 10.1002/Emmm.201100124 |
0.358 |
|
| 2011 |
Poopak B, Rezvani H, Difeo A, Martignetti JA, Khosravipour G, Yousefian A, Farahani K, Haghnejad Doshanlo F, Saki N. The first report of homozygous May-Hegglin anomaly E1841K mutation. European Journal of Haematology. 86: 357. PMID 21083612 DOI: 10.1111/J.1600-0609.2010.01553.X |
0.607 |
|
| 2011 |
Radbill BD, Gupta R, Ramirez MC, DiFeo A, Martignetti JA, Alvarez CE, Friedman SL, Narla G, Vrabie R, Bowles R, Saiman Y, Bansal MB. Loss of matrix metalloproteinase-2 amplifies murine toxin-induced liver fibrosis by upregulating collagen I expression. Digestive Diseases and Sciences. 56: 406-16. PMID 20563750 DOI: 10.1007/S10620-010-1296-0 |
0.585 |
|
| 2011 |
Mosig R, Senturk E, Shah H, Cohen S, Sachidanandam R, Eliasen C, Glucksman M, Chee M, Dottino P, Martignetti J. RNASeq identifies germline and tumor-specific mutations in a hereditary cervical cancer syndrome: Successful proof-of-principle study for gynecologic cancer gene discovery Gynecologic Oncology. 120: S60. DOI: 10.1016/J.Ygyno.2010.12.145 |
0.79 |
|
| 2011 |
Bradley W, Dottino P, Rahaman J, DiFeo A, Martignetti J. The tumor suppressor KLF6, lost in a majority of ovarian cancer cases, represses VEGF expression levels Gynecologic Oncology. 120: S57. DOI: 10.1016/J.Ygyno.2010.12.137 |
0.657 |
|
| 2011 |
DiFeo A, Sennet R, Huang F, Levine D, Kalir T, van de Rijn M, Dottino P, Martignetti J. KLF6-SV1 is a novel uterine leiomyosarcoma gene: From transgenic mouse model to human disease Gynecologic Oncology. 120: S8. DOI: 10.1016/J.Ygyno.2010.12.022 |
0.588 |
|
| 2010 |
Rodríguez E, Aburjania N, Priedigkeit NM, DiFeo A, Martignetti JA. Nucleo-cytoplasmic localization domains regulate Krüppel-like factor 6 (KLF6) protein stability and tumor suppressor function. Plos One. 5. PMID 20844588 DOI: 10.1371/Journal.Pone.0012639 |
0.645 |
|
| 2010 |
Senturk E, Cohen S, Dottino PR, Martignetti JA. A critical re-appraisal of BRCA1 methylation studies in ovarian cancer. Gynecologic Oncology. 119: 376-83. PMID 20797776 DOI: 10.1016/J.Ygyno.2010.07.026 |
0.425 |
|
| 2009 |
DiFeo A, Narla G, Martignetti JA. Emerging roles of Kruppel-like factor 6 and Kruppel-like factor 6 splice variant 1 in ovarian cancer progression and treatment. The Mount Sinai Journal of Medicine, New York. 76: 557-66. PMID 20014424 DOI: 10.1002/Msj.20150 |
0.682 |
|
| 2009 |
Rodríguez E, Martignetti JA. The Krüppel traffic report: cooperative signals direct KLF8 nuclear transport. Cell Research. 19: 1041-3. PMID 19727130 DOI: 10.1038/Cr.2009.103 |
0.321 |
|
| 2009 |
Sanborn KB, Rak GD, Maru SY, Demers K, Difeo A, Martignetti JA, Betts MR, Favier R, Banerjee PP, Orange JS. Myosin IIA associates with NK cell lytic granules to enable their interaction with F-actin and function at the immunological synapse. Journal of Immunology (Baltimore, Md. : 1950). 182: 6969-84. PMID 19454694 DOI: 10.4049/Jimmunol.0804337 |
0.576 |
|
| 2009 |
Difeo A, Huang F, Sangodkar J, Terzo EA, Leake D, Narla G, Martignetti JA. KLF6-SV1 is a novel antiapoptotic protein that targets the BH3-only protein NOXA for degradation and whose inhibition extends survival in an ovarian cancer model. Cancer Research. 69: 4733-41. PMID 19435908 DOI: 10.1158/0008-5472.Can-08-4282 |
0.661 |
|
| 2009 |
Deuquet J, Abrami L, Difeo A, Ramirez MC, Martignetti JA, van der Goot FG. Systemic hyalinosis mutations in the CMG2 ectodomain leading to loss of function through retention in the endoplasmic reticulum. Human Mutation. 30: 583-9. PMID 19191226 DOI: 10.1002/Humu.20872 |
0.62 |
|
| 2009 |
Sangodkar J, Shi J, DiFeo A, Schwartz R, Bromberg R, Choudhri A, McClinch K, Hatami R, Scheer E, Kremer-Tal S, Martignetti JA, Hui A, Leung WK, Friedman SL, Narla G. Functional role of the KLF6 tumour suppressor gene in gastric cancer. European Journal of Cancer (Oxford, England : 1990). 45: 666-76. PMID 19101139 DOI: 10.1016/J.Ejca.2008.11.009 |
0.659 |
|
| 2009 |
DiFeo A, Martignetti JA, Narla G. The role of KLF6 and its splice variants in cancer therapy. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 12: 1-7. PMID 19097929 DOI: 10.1016/J.Drup.2008.11.001 |
0.697 |
|
| 2009 |
Tuysuz B, Mosig R, Altun G, Sancak S, Glucksman MJ, Martignetti JA. A novel matrix metalloproteinase 2 (MMP2) terminal hemopexin domain mutation in a family with multicentric osteolysis with nodulosis and arthritis with cardiac defects. European Journal of Human Genetics : Ejhg. 17: 565-72. PMID 18985071 DOI: 10.1038/Ejhg.2008.204 |
0.758 |
|
| 2008 |
Hartel M, Narla G, Wente MN, Giese NA, Martignoni ME, Martignetti JA, Friess H, Friedman SL. Increased alternative splicing of the KLF6 tumour suppressor gene correlates with prognosis and tumour grade in patients with pancreatic cancer. European Journal of Cancer (Oxford, England : 1990). 44: 1895-903. PMID 18691883 DOI: 10.1016/J.Ejca.2008.06.030 |
0.416 |
|
| 2008 |
Narla G, DiFeo A, Fernandez Y, Dhanasekaran S, Huang F, Sangodkar J, Hod E, Leake D, Friedman SL, Hall SJ, Chinnaiyan AM, Gerald WL, Rubin MA, Martignetti JA. KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis. The Journal of Clinical Investigation. 118: 2711-21. PMID 18596922 DOI: 10.1172/Jci34780 |
0.667 |
|
| 2008 |
Yea S, Narla G, Zhao X, Garg R, Tal-Kremer S, Hod E, Villanueva A, Loke J, Tarocchi M, Akita K, Shirasawa S, Sasazuki T, Martignetti JA, Llovet JM, Friedman SL. Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma. Gastroenterology. 134: 1521-31. PMID 18471523 DOI: 10.1053/J.Gastro.2008.02.015 |
0.384 |
|
| 2008 |
DiFeo A, Feld L, Rodriguez E, Wang C, Beer DG, Martignetti JA, Narla G. A functional role for KLF6-SV1 in lung adenocarcinoma prognosis and chemotherapy response. Cancer Research. 68: 965-70. PMID 18250346 DOI: 10.1158/0008-5472.Can-07-2604 |
0.648 |
|
| 2008 |
Lindvall LE, Kormeili T, Chen E, Ramirez MC, Grum-Tokars V, Glucksman MJ, Martignetti JA, Zaragoza MV, Dyson SW. Infantile systemic hyalinosis: Case report and review of the literature. Journal of the American Academy of Dermatology. 58: 303-7. PMID 18222328 DOI: 10.1016/J.Jaad.2007.06.008 |
0.306 |
|
| 2007 |
Teixeira MS, Camacho-Vanegas O, Fernandez Y, Narla G, DiFeo A, Lee B, Kalir T, Friedman SL, Schlecht NF, Genden EM, Urken M, Brandwein-Gensler M, Martignetti JA. KLF6 allelic loss is associated with tumor recurrence and markedly decreased survival in head and neck squamous cell carcinoma. International Journal of Cancer. 121: 1976-83. PMID 17621627 DOI: 10.1002/Ijc.22926 |
0.687 |
|
| 2007 |
Camacho-Vanegas O, Narla G, Teixeira MS, DiFeo A, Misra A, Singh G, Chan AM, Friedman SL, Feuerstein BG, Martignetti JA. Functional inactivation of the KLF6 tumor suppressor gene by loss of heterozygosity and increased alternative splicing in glioblastoma. International Journal of Cancer. Journal International Du Cancer. 121: 1390-5. PMID 17514651 DOI: 10.1002/Ijc.22809 |
0.676 |
|
| 2007 |
Mosig RA, Dowling O, DiFeo A, Ramirez MC, Parker IC, Abe E, Diouri J, Aqeel AA, Wylie JD, Oblander SA, Madri J, Bianco P, Apte SS, Zaidi M, Doty SB, ... ... Martignetti JA, et al. Loss of MMP-2 disrupts skeletal and craniofacial development and results in decreased bone mineralization, joint erosion and defects in osteoblast and osteoclast growth. Human Molecular Genetics. 16: 1113-23. PMID 17400654 DOI: 10.1093/Hmg/Ddm060 |
0.765 |
|
| 2007 |
Phadke SR, Ramirez M, Difeo A, Martignetti JA, Girisha KM. Torg-Winchester syndrome: lack of efficacy of pamidronate therapy. Clinical Dysmorphology. 16: 95-100. PMID 17351352 DOI: 10.1097/Mcd.0B013E3280147187 |
0.6 |
|
| 2007 |
Antaya RJ, Cajaiba MM, Madri J, Lopez MA, Ramirez MCM, Martignetti JA, Reyes-Múgica M. Juvenile hyaline fibromatosis and infantile systemic hyalinosis overlap associated with a novel mutation in capillary morphogenesis protein-2 gene American Journal of Dermatopathology. 29: 99-103. PMID 17284973 DOI: 10.1097/01.Dad.0000245636.39098.E5 |
0.333 |
|
| 2007 |
Kremer-Tal S, Narla G, Chen Y, Hod E, DiFeo A, Yea S, Lee JS, Schwartz M, Thung SN, Fiel IM, Banck M, Zimran E, Thorgeirsson SS, Mazzaferro V, Bruix J, ... Martignetti JA, et al. Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. Journal of Hepatology. 46: 645-54. PMID 17196295 DOI: 10.1016/J.Jhep.2006.10.012 |
0.623 |
|
| 2007 |
Kupferman ME, Rhee JS, Teixeira MS, Camacho-Vanegas O, Fernandez Y, Narla G, Difeo A, Schlecht NF, Brandwein-Gensler M, Martignetti JA. 10:30: KLF6 LOH Is Linked to Recurrence and Lower Survival in HNSSC Otolaryngology–Head and Neck Surgery. 137: P77-P78. DOI: 10.1016/J.Otohns.2007.06.095 |
0.58 |
|
| 2006 |
Utsch B, DiFeo A, Kujat A, Karle S, Schuster V, Lenk H, Jacobs U, Müller M, Dötsch J, Rascher W, Reutter H, Martignetti JA, Ludwig M, Tröbs RB. Bladder exstrophy and Epstein type congenital macrothrombocytopenia: evidence for a common cause? American Journal of Medical Genetics. Part A. 140: 2251-3. PMID 16969870 DOI: 10.1002/Ajmg.A.31454 |
0.578 |
|
| 2006 |
DiFeo A, Narla G, Hirshfeld J, Camacho-Vanegas O, Narla J, Rose SL, Kalir T, Yao S, Levine A, Birrer MJ, Bonome T, Friedman SL, Buller RE, Martignetti JA. Roles of KLF6 and KLF6-SV1 in ovarian cancer progression and intraperitoneal dissemination. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 3730-9. PMID 16778100 DOI: 10.1158/1078-0432.Ccr-06-0054 |
0.674 |
|
| 2006 |
DiFeo A, Narla G, Camacho-Vanegas O, Nishio H, Rose SL, Buller RE, Friedman SL, Walsh MJ, Martignetti JA. E-cadherin is a novel transcriptional target of the KLF6 tumor suppressor. Oncogene. 25: 6026-31. PMID 16702959 DOI: 10.1038/Sj.Onc.1209611 |
0.638 |
|
| 2006 |
Kirschenbaum A, Liu XH, Yao S, Narla G, Friedman SL, Martignetti JA, Levine AC. Sex steroids have differential effects on growth and gene expression in primary human prostatic epithelial cell cultures derived from the peripheral versus transition zones. Carcinogenesis. 27: 216-24. PMID 16123118 DOI: 10.1093/Carcin/Bgi219 |
0.316 |
|
| 2005 |
Park JH, Eliyahu E, Narla G, DiFeo A, Martignetti JA, Schuchman EH. KLF6 is one transcription factor involved in regulating acid ceramidase gene expression Biochimica Et Biophysica Acta - Gene Structure and Expression. 1732: 82-87. PMID 16500425 DOI: 10.1016/J.Bbaexp.2006.01.002 |
0.635 |
|
| 2005 |
Li D, Yea S, Dolios G, Martignetti JA, Narla G, Wang R, Walsh MJ, Friedman SL. Regulation of Kruppel-like factor 6 tumor suppressor activity by acetylation. Cancer Research. 65: 9216-25. PMID 16230382 DOI: 10.1158/0008-5472.Can-05-1040 |
0.395 |
|
| 2005 |
Narla G, DiFeo A, Yao S, Banno A, Hod E, Reeves HL, Qiao RF, Camacho-Vanegas O, Levine A, Kirschenbaum A, Chan AM, Friedman SL, Martignetti JA. Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread. Cancer Research. 65: 5761-8. PMID 15994951 DOI: 10.1158/0008-5472.Can-05-0217 |
0.669 |
|
| 2005 |
Narla G, Difeo A, Reeves HL, Schaid DJ, Hirshfeld J, Hod E, Katz A, Isaacs WB, Hebbring S, Komiya A, McDonnell SK, Wiley KE, Jacobsen SJ, Isaacs SD, Walsh PC, ... ... Martignetti JA, et al. A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. Cancer Research. 65: 1213-22. PMID 15735005 DOI: 10.1158/0008-5472.Can-04-4249 |
0.656 |
|
| 2004 |
Kremer-Tal S, Reeves HL, Narla G, Thung SN, Schwartz M, Difeo A, Katz A, Bruix J, Bioulac-Sage P, Martignetti JA, Friedman SL. Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma. Hepatology (Baltimore, Md.). 40: 1047-52. PMID 15486921 DOI: 10.1002/Hep.20460 |
0.653 |
|
| 2004 |
Kimmelman AC, Qiao RF, Narla G, Banno A, Lau N, Bos PD, Nuñez Rodriguez N, Liang BC, Guha A, Martignetti JA, Friedman SL, Chan AM. Suppression of glioblastoma tumorigenicity by the Kruppel-like transcription factor KLF6. Oncogene. 23: 5077-83. PMID 15064720 DOI: 10.1038/Sj.Onc.1207662 |
0.437 |
|
| 2004 |
Reeves HL, Narla G, Ogunbiyi O, Haq AI, Katz A, Benzeno S, Hod E, Harpaz N, Goldberg S, Tal-Kremer S, Eng FJ, Arthur MJ, Martignetti JA, Friedman SL. Kruppel-like factor 6 (KLF6) is a tumor-suppressor gene frequently inactivated in colorectal cancer. Gastroenterology. 126: 1090-103. PMID 15057748 DOI: 10.1053/J.Gastro.2004.01.005 |
0.436 |
|
| 2003 |
Toren A, Rozenfeld-Granot G, Heath KE, Amariglio N, Rocca B, Crosson J, Epstein CJ, Laghi F, Landolfi R, Carlsson LE, Argraves S, Bizzaro N, Moxey-Mims M, Brok-Simoni F, Martignetti JA, et al. MYH9 spectrum of autosomal-dominant giant platelet syndromes: unexpected association with fibulin-1 variant-D inactivation. American Journal of Hematology. 74: 254-62. PMID 14635206 DOI: 10.1002/Ajh.10425 |
0.361 |
|
| 2003 |
Dowling O, Difeo A, Ramirez MC, Tukel T, Narla G, Bonafe L, Kayserili H, Yuksel-Apak M, Paller AS, Norton K, Teebi AS, Grum-Tokars V, Martin GS, Davis GE, Glucksman MJ, ... Martignetti JA, et al. Mutations in capillary morphogenesis gene-2 result in the allelic disorders juvenile hyaline fibromatosis and infantile systemic hyalinosis. American Journal of Human Genetics. 73: 957-66. PMID 12973667 DOI: 10.1086/378781 |
0.656 |
|
| 2003 |
Narla G, Friedman SL, Martignetti JA. Krüppel cripples prostate cancer: KLF6 progress and prospects. The American Journal of Pathology. 162: 1047-52. PMID 12651597 DOI: 10.1016/S0002-9440(10)63901-6 |
0.344 |
|
| 2003 |
Hirshfeld J, Narla G, Difeo A, Kalir T, Buller R, Friedman S, Martignetti J. KLF6 POLYMORPHISM IN PROSTATE CANCER REVEALS A NOVEL MECHANISM OF TUMOR SUPPRESSOR GENE INACTIVATION. Journal of Investigative Medicine. 51: 336.2-337. DOI: 10.1136/Jim-51-06-21 |
0.645 |
|
| 2001 |
Narla G, Heath KE, Reeves HL, Li D, Giono LE, Kimmelman AC, Glucksman MJ, Narla J, Eng FJ, Chan AM, Ferrari AC, Martignetti JA, Friedman SL. KLF6, a candidate tumor suppressor gene mutated in prostate cancer. Science (New York, N.Y.). 294: 2563-6. PMID 11752579 DOI: 10.1126/Science.1066326 |
0.434 |
|
| 2001 |
Heath KE, Campos-Barros A, Toren A, Rozenfeld-Granot G, Carlsson LE, Savige J, Denison JC, Gregory MC, White JG, Barker DF, Greinacher A, Epstein CJ, Glucksman MJ, Martignetti JA. Nonmuscle myosin heavy chain IIA mutations define a spectrum of autosomal dominant macrothrombocytopenias: May-Hegglin anomaly and Fechtner, Sebastian, Epstein, and Alport-like syndromes. American Journal of Human Genetics. 69: 1033-45. PMID 11590545 DOI: 10.1086/324267 |
0.35 |
|
| 2001 |
Martignetti JA, Aqeel AA, Sewairi WA, Boumah CE, Kambouris M, Mayouf SA, Sheth KV, Eid WA, Dowling O, Harris J, Glucksman MJ, Bahabri S, Meyer BF, Desnick RJ. Mutation of the matrix metalloproteinase 2 gene (MMP2) causes a multicentric osteolysis and arthritis syndrome. Nature Genetics. 28: 261-5. PMID 11431697 DOI: 10.1038/90100 |
0.387 |
|
| 2000 |
Yang T, Martignetti JA, Massa SM, Longo FM. Leukocyte common-antigen-related tyrosine phosphatase receptor: altered expression of mRNA and protein in the New England Deaconess Hospital rat line exhibiting spontaneous pheochromocytoma. Carcinogenesis. 21: 125-31. PMID 10657947 DOI: 10.1093/Carcin/21.2.125 |
0.352 |
|
| 2000 |
Martignetti JA, Gelb BD, Pierce H, Picci P, Desnick RJ. Malignant fibrous histiocytoma: inherited and sporadic forms have loss of heterozygosity at chromosome bands 9p21-22-evidence for a common genetic defect. Genes, Chromosomes and Cancer. 27: 191-195. PMID 10612808 DOI: 10.1002/(Sici)1098-2264(200002)27:2<191::Aid-Gcc11>3.0.Co;2-L |
0.37 |
|
| 1999 |
Wasserstein MP, Martignetti JA, Zeitlin R, Lumerman H, Solomon M, Grace ME, Desnick RJ. Type 1 Gaucher disease presenting with extensive mandibular lytic lesions: identification and expression of a novel acid beta-glucosidase mutation. American Journal of Medical Genetics. 84: 334-9. PMID 10340647 DOI: 10.1002/(Sici)1096-8628(19990604)84:4<334::Aid-Ajmg5>3.0.Co;2-P |
0.312 |
|
| 1999 |
Martignetti JA, Desnick RJ, Aliprandis E, Norton KI, Hardcastle P, Nade S, Gelb BD. Diaphyseal medullary stenosis with malignant fibrous histiocytoma: a hereditary bone dysplasia/cancer syndrome maps to 9p21-22. American Journal of Human Genetics. 64: 801-7. PMID 10053015 DOI: 10.1086/302297 |
0.39 |
|
| 1998 |
Martignetti JA, Desnick RJ, Gelb BD. From Hereditary Cancer Syndrome to Sporadic Cancer Etiology: Genetic Linkage of DMS-MFH to Chromosome 9p21-22 • 724 Pediatric Research. 43: 126-126. DOI: 10.1203/00006450-199804001-00745 |
0.404 |
|
| 1996 |
Norton KI, Wagreich JM, Granowetter L, Martignetti JA. Diaphyseal medullary stenosis (sclerosis) with bone malignancy (malignant fibrous histiocytoma): Hardcastle syndrome. Pediatric Radiology. 26: 675-7. PMID 8781110 DOI: 10.1007/Bf01356833 |
0.309 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2003 |
Zhang C, Xie Y, Martignetti JA, Yeo TT, Massa SM, Longo FM. A candidate chimeric mammalian mRNA transcript is derived from distinct chromosomes and is associated with nonconsensus splice junction motifs. Dna and Cell Biology. 22: 303-15. PMID 12941158 DOI: 10.1089/104454903322216653 |
0.3 |
|
| 2023 |
Reid K, Camacho-Vanegas O, Pandya D, Camacho SC, Qiao RF, Kalir T, Padron MM, Beddoe AM, Dottino P, Martignetti JA. DEEP MOLECULAR TRACKING OVER THE 12-YEAR DEVELOPMENT OF ENDOMETRIAL CANCER FROM HYPERPLASIA IN A SINGLE PATIENT. Cold Spring Harbor Molecular Case Studies. PMID 37848227 DOI: 10.1101/mcs.a006311 |
0.3 |
|
| 2016 |
Martignetti J, Reva B, Elena P, Camacho-Vanegas O, Rykunov D, Kendall S, Shah H, Nair N, Strahl M, Hamou W, Kalir T, Schadt E, Sebra R, Dottino P. A pre-operative, diagnostic gene panel for guiding primary treatment choices in endometrial cancer: Advancing beyond the decades-old technology of dilation and curettage (D&C) European Journal of Cancer. 61. DOI: 10.1016/S0959-8049(16)61103-6 |
0.297 |
|
| 2000 |
Al Aqeel A, Al Sewairi W, Edress B, Gorlin RJ, Desnick RJ, Martignetti JA. Inherited multicentric osteolysis with arthritis: a variant resembling Torg syndrome in a Saudi family. American Journal of Medical Genetics. 93: 11-8. PMID 10861676 DOI: 10.1002/1096-8628(20000703)93:1<11::Aid-Ajmg3>3.0.Co;2-3 |
0.296 |
|
| 2013 |
Shalata A, Ramirez MC, Desnick RJ, Priedigkeit N, Buettner C, Lindtner C, Mahroum M, Abdul-Ghani M, Dong F, Arar N, Camacho-Vanegas O, Zhang R, Camacho SC, Chen Y, Ibdah M, ... ... Martignetti JA, et al. Morbid obesity resulting from inactivation of the ciliary protein CEP19 in humans and mice. American Journal of Human Genetics. 93: 1061-71. PMID 24268657 DOI: 10.1016/J.Ajhg.2013.10.025 |
0.294 |
|
| 2011 |
Martignetti JA, Dottino PR. Response to the Letter to the Editor by Bol and van Diest regarding the review article “BRCA1 methylation and BRCA1 mutations in ovarian cancer” Gynecologic Oncology. 122: 459-460. DOI: 10.1016/J.Ygyno.2011.05.013 |
0.293 |
|
| 1993 |
Martignetti JA, Brosius J. Neural BC1 RNA as an evolutionary marker: guinea pig remains a rodent Proceedings of the National Academy of Sciences of the United States of America. 90: 9698-9702. PMID 7692450 DOI: 10.1073/Pnas.90.20.9698 |
0.287 |
|
| 2020 |
Mieszawska AJ, Wlodarczyk MT, Dragulska SA, Poursharifi M, Chen Y, Martignetti JA. pH‐responsive nanoparticles for Pt (II) delivery to ovarian cancer cells. The Faseb Journal. 34: 1-1. DOI: 10.1096/Fasebj.2020.34.S1.02911 |
0.286 |
|
| 2014 |
Hennessy E, O'Callaghan J, Mooij MJ, Legendre C, Camacho-Vanegas O, Camacho SC, Adams C, Martignetti JA, O'Gara F. The impact of simvastatin on pulmonary effectors of Pseudomonas aeruginosa infection. Plos One. 9: e102200. PMID 25010049 DOI: 10.1371/Journal.Pone.0102200 |
0.285 |
|
| 2006 |
Shieh JT, Swidler P, Martignetti JA, Ramirez MC, Balboni I, Kaplan J, Kennedy J, Abdul-Rahman O, Enns GM, Sandborg C, Slavotinek A, Hoyme HE. Systemic hyalinosis: a distinctive early childhood-onset disorder characterized by mutations in the anthrax toxin receptor 2 gene (ANTRX2). Pediatrics. 118: e1485-92. PMID 17043134 DOI: 10.1542/Peds.2006-0824 |
0.281 |
|
| 2020 |
Swierczek S, Pandya D, Billaud J, Dominguez IV, Farisello S, Sieber S, Chen Y, Chuang LT, Andikyan V, Martignetti J. Integrated genomic and functional analysis of patient-derived sarcoma cell lines validates their use for candidate treatment discovery including knockdown of a novel BCOR fusion gene. Journal of Clinical Oncology. 38. DOI: 10.1200/Jco.2020.38.15_Suppl.E23572 |
0.281 |
|
| 2014 |
Weber U, Rodriguez E, Martignetti J, Mlodzik M. Luna, a Drosophila KLF6/KLF7, is maternally required for synchronized nuclear and centrosome cycles in the preblastoderm embryo. Plos One. 9: e96933. PMID 24915236 DOI: 10.1371/Journal.Pone.0096933 |
0.28 |
|
| 1994 |
Kim J, Martignetti JA, Shen MR, Brosius J, Deininger P. Rodent BC1 RNA gene as a master gene for ID element amplification. Proceedings of the National Academy of Sciences of the United States of America. 91: 3607-11. PMID 8170955 DOI: 10.1073/Pnas.91.9.3607 |
0.278 |
|
| 2003 |
Reeves H, Arthur M, Narla G, Oginbiyi O, Haque A, Katz A, Goldberg S, Harpaz N, Martignetti J, Friedman S. The role of kruppel-like factor 6 (KLF6) in colorectal neoplasia Gastroenterology. 124: A13. DOI: 10.1016/S0016-5085(03)80064-1 |
0.275 |
|
| 2020 |
Poursharifi M, dragulska SA, Chen Y, Martignetti J, Mieszawska A. The development of peptide‐coated nanoparticles for targeting and drug delivery to cancer cells The Faseb Journal. 34: 1-1. DOI: 10.1096/Fasebj.2020.34.S1.02042 |
0.274 |
|
| 1996 |
Gelb BD, Moissoglu K, Zhang J, Martignetti JA, Brömme D, Desnick RJ. Cathepsin K: Isolation and Characterization of the Murine cDNA and Genomic Sequence, the Homologue of the Human Pycnodysostosis Gene Biochemical and Molecular Medicine. 59: 200-206. PMID 8986645 DOI: 10.1006/Bmme.1996.0088 |
0.272 |
|
| 1995 |
Martignetti JA, Brosius J. BC1 RNA: transcriptional analysis of a neural cell-specific RNA polymerase III transcript. Molecular and Cellular Biology. 15: 1642-1650. PMID 7862155 DOI: 10.1128/Mcb.15.3.1642 |
0.271 |
|
| 2024 |
Pandya D, Tomita S, Rhenals MP, Swierczek S, Reid K, Camacho-Vanegas O, Camacho C, Engelman K, Polukort S, RoseFigura J, Chuang L, Andikyan V, Cohen S, Fiedler P, Sieber S, ... ... Martignetti JA, et al. Mutations in cancer-relevant genes are ubiquitous in histologically normal endometrial tissue. Gynecologic Oncology. 185: 194-201. PMID 38452634 DOI: 10.1016/j.ygyno.2024.02.027 |
0.27 |
|
| 2020 |
Dragulska SA, Poursharifi M, Cheng Y, Martignetti J, Mieszawska AJ. Peptide‐stabilized nanomaterials for drug delivery and cancer therapy The Faseb Journal. 34: 1-1. DOI: 10.1096/Fasebj.2020.34.S1.02041 |
0.266 |
|
| 2021 |
Pandya D, Shah M, Kaplan F, Martino C, Levy G, Kazanjian M, Batter S, Martignetti J, Frank RC. Treatment-emergent neuroendocrine prostate cancer with a germline mutation: identification of a candidate reversion mutation associated with platinum/PARP-inhibitor resistance. Cold Spring Harbor Molecular Case Studies. 7. PMID 33608381 DOI: 10.1101/mcs.a005801 |
0.265 |
|
| 1993 |
Martignetti JA, Brosius J. BC200 RNA: a neural RNA polymerase III product encoded by a monomeric Alu element Proceedings of the National Academy of Sciences of the United States of America. 90: 11563-11567. PMID 8265590 DOI: 10.1073/Pnas.90.24.11563 |
0.265 |
|
| 2000 |
Martignetti JA, Heath KE, Harris J, Bizzaro N, Savoia A, Balduini CL, Desnick RJ. The gene for May-Hegglin anomaly localizes to a <1-Mb region chromosome 22q12.3-13.1 American Journal of Human Genetics. 66: 1449-1454. PMID 10739770 DOI: 10.1086/302873 |
0.262 |
|
| 1999 |
Aliprandis E, Harris J, Yoo B, Gelb BD, Martignetti JA. Isolation, characterization, and mapping of four novel polymorphic markers and an H3.3B pseudogene to chromosome 9p21-22. Journal of Human Genetics. 44: 348-9. PMID 10496081 DOI: 10.1007/S100380050174 |
0.26 |
|
| 2011 |
Martignetti J, Narla G, Friedman S. KLF6 (Kruppel like factor 6) Atlas of Genetics and Cytogenetics in Oncology and Haematology. DOI: 10.4267/2042/38449 |
0.259 |
|
| 2019 |
Pandya D, Camacho SC, Padron MM, Camacho-Vanegas O, Billaud JN, Beddoe AM, Irish J, Yoxtheimer L, Kalir T, RoseFigura J, Dottino P, Martignetti JA. Rapid development and use of patient-specific ctDNA biomarkers to avoid a "rash decision" in an ovarian cancer patient. Cold Spring Harbor Molecular Case Studies. PMID 31628202 DOI: 10.1101/mcs.a004648 |
0.259 |
|
| 2008 |
Schwartz M, Dvorchik I, Roayaie S, Fiel MI, Finkelstein S, Marsh JW, Martignetti JA, Llovet JM. Liver transplantation for hepatocellular carcinoma: extension of indications based on molecular markers. Journal of Hepatology. 49: 581-8. PMID 18602719 DOI: 10.1016/J.Jhep.2008.03.032 |
0.257 |
|
| 2008 |
Villanueva A, Chiang DY, Newell P, Peix J, Thung S, Alsinet C, Tovar V, Roayaie S, Minguez B, Sole M, Battiston C, Van Laarhoven S, Fiel MI, Di Feo A, Hoshida Y, ... ... Martignetti JA, et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology. 135: 1972-83, 1983.e1-11. PMID 18929564 DOI: 10.1053/J.Gastro.2008.08.008 |
0.257 |
|
| 1991 |
Bankier AT, Beck S, Bohni R, Brown CM, Cerny R, Chee MS, Hutchison CA, Kouzarides T, Martignetti JA, Preddie E, Satchwell SC, Tomlinson P, Weston KM, Barrell BG. The DNA sequence of the human cytomegalovirus genome Dna Sequence : the Journal of Dna Sequencing and Mapping. 2: 1-12. PMID 1666311 DOI: 10.3109/10425179109008433 |
0.254 |
|
| 2005 |
Teng MS, Brandwein-Gensler MS, Teixeira MS, Martignetti JA, Duffey DC. A study of TRAIL receptors in squamous cell carcinoma of the head and neck. Archives of Otolaryngology--Head & Neck Surgery. 131: 407-12. PMID 15897419 DOI: 10.1001/Archotol.131.5.407 |
0.243 |
|
| 2013 |
Favier R, Feriel J, Favier M, Denoyelle F, Martignetti JA. First successful use of eltrombopag before surgery in a child with MYH9-related thrombocytopenia. Pediatrics. 132: e793-5. PMID 23940247 DOI: 10.1542/Peds.2012-3807 |
0.24 |
|
| 2018 |
Wlodarczyk MT, Dragulska SA, Camacho-Vanegas O, Dottino PR, Jarzęcki AA, Martignetti JA, Mieszawska AJ. Platinum (II) complex-nuclear localization sequence peptide hybrid for overcoming platinum resistance in cancer therapy. Acs Biomaterials Science & Engineering. 4: 463-467. PMID 32042890 DOI: 10.1021/Acsbiomaterials.7B00921 |
0.238 |
|
| 1991 |
Martignetti JA, Barrell BG. Sequence of the HindIII T fragment of human cytomegalovirus, which encodes a DNA helicase Journal of General Virology. 72: 1113-1121. PMID 1851811 DOI: 10.1099/0022-1317-72-5-1113 |
0.236 |
|
| 2000 |
Tullai JW, Cummins PM, Pabon A, Roberts JL, Lopingco MC, Shrimpton CN, Smith AI, Martignetti JA, Ferro ES, Glucksman MJ. The neuropeptide processing enzyme EC 3.4.24.15 is modulated by protein kinase A phosphorylation. The Journal of Biological Chemistry. 275: 36514-22. PMID 10969067 DOI: 10.1074/Jbc.M001843200 |
0.227 |
|
| 1990 |
Chee MS, Bankier AT, Beck S, Bohni R, Brown CM, Cerny R, Horsnell T, Hutchison CA, Kouzarides T, Martignetti JA, Preddie E, Satchwell SC, Tomlinson P, Weston KM, Barrell BG. Analysis of the protein-coding content of the sequence of human cytomegalovirus strain AD169 Current Topics in Microbiology and Immunology. 154: 125-169. PMID 2161319 DOI: 10.1007/978-3-642-74980-3_6 |
0.226 |
|
| 2023 |
Dou Y, Katsnelson L, Gritsenko MA, Hu Y, Reva B, Hong R, Wang YT, Kolodziejczak I, Lu RJ, Tsai CF, Bu W, Liu W, Guo X, An E, Arend RC, ... ... Martignetti JA, et al. Proteogenomic insights suggest druggable pathways in endometrial carcinoma. Cancer Cell. PMID 37567170 DOI: 10.1016/j.ccell.2023.07.007 |
0.208 |
|
| 1992 |
Kennedy JL, Honer WG, Kaufmann CA, Martignetti JA, Brosius J, Kidd KK. Two RFLPs near HOX2@/NGFR at locus D17S444E. Nucleic Acids Research. 20: 1171. PMID 1372406 DOI: 10.1093/Nar/20.5.1171 |
0.208 |
|
| 2019 |
Dragulska SA, Wlodarczyk MT, Poursharifi M, Martignetti JA, Mieszawska AJ. A Tripeptide-Stabilized Nanoemulsion of Oleic Acid. Journal of Visualized Experiments : Jove. PMID 30882795 DOI: 10.3791/59034 |
0.19 |
|
| 2018 |
Schussler E, Linkner RV, Levitt J, Mehta L, Martignetti JA, Oishi K. Protein-losing enteropathy and joint contractures caused by a novel homozygous ANTXR2 mutation. Advances in Genomics and Genetics. 8: 17-21. PMID 30050362 DOI: 10.2147/AGG.S159077 |
0.189 |
|
| 2020 |
Wlodarczyk MT, Dragulska S, Poursharifi M, Cheng Y, Martignetti J, Mieszawska A. Microenvironment‐responsive nanoparticle platform for anticancer drug delivery. The Faseb Journal. 34: 1-1. DOI: 10.1096/Fasebj.2020.34.S1.09257 |
0.184 |
|
| 2020 |
Sarker H, Hardy E, Haimour A, Karim MA, Scholl-Bürgi S, Martignetti JA, Botto LD, Fernandez-Patron C. Comparative Serum Analyses Identify Cytokines and Hormones Commonly Dysregulated as Well as Implicated in Promoting Osteolysis in MMP-2-Deficient Mice and Children. Frontiers in Physiology. 11: 568718. PMID 33101055 DOI: 10.3389/fphys.2020.568718 |
0.172 |
|
| 2018 |
Dragulska SA, Chen Y, Wlodarczyk MT, Poursharifi M, Dottino P, Ulijn RV, Martignetti JA, Mieszawska AJ. Tripeptide-Stabilized Oil-in-Water Nanoemulsion of an Oleic Acids-Platinum(II) Conjugate as an Anticancer Nanomedicine. Bioconjugate Chemistry. PMID 30001618 DOI: 10.1021/acs.bioconjchem.8b00409 |
0.158 |
|
| 2023 |
Wlodarczyk MT, Dragulska SA, Chen Y, Poursharifi M, Acosta Santiago M, Martignetti JA, Mieszawska AJ. Pt(II)-PLGA Hybrid in a pH-Responsive Nanoparticle System Targeting Ovarian Cancer. Pharmaceutics. 15. PMID 36839929 DOI: 10.3390/pharmaceutics15020607 |
0.096 |
|
| 2022 |
Dragulska SA, Poursharifi M, Chen Y, Wlodarczyk MT, Acosta Santiago M, Dottino P, Martignetti JA, Mieszawska AJ. Engineering and Validation of a Peptide-Stabilized Poly(lactic--glycolic) Acid Nanoparticle for Targeted Delivery of a Vascular Disruptive Agent in Cancer Therapy. Bioconjugate Chemistry. PMID 36367382 DOI: 10.1021/acs.bioconjchem.2c00418 |
0.09 |
|
| 2004 |
Martignetti J. Five (un)easy pieces: the MYH9-related giant platelet syndromes. Haematologica. 87: 897-8. PMID 12217798 |
0.07 |
|
| 2016 |
Lanoue J, Jacobson KB, Ooka K, Singh C, Camacho-Vanegas O, Martignetti JA, Levitt J, Phelps RG. Porokeratotic Adnexal Ostial Nevus-Report of a Case With Unusual Clinical and Histologic Features. Skinmed. 14: 221-4. PMID 27502264 |
0.035 |
|
| Hide low-probability matches. |